Over the past five years, Developmental Funds have been used to support Pilot Projects, recruitment of new investigators, and development of new Shared Resources and services to further UCCCC strategic goals, including a) Precision Medicine and the UCCCC Personalized Cancer Care Consortium (PCCC); b) Cancer Prevention and Population Medicine; and c) Cancer Survivorship, Outcomes, and Economics as well as interdisciplinary and interprogrammatic collaborations. From 2013-2016, a CCSG investment of $939,622 has yielded a remarkable return of $12,456,464 in peer-reviewed support, as well as publications and programmatic development. Support for four new investigators has contributed to enhancements of the Molecular Mechanisms of Cancer, Clinical and Experimental Therapeutics, and Cancer Prevention and Control Programs. Recruitments include: Megan McNerney, MD, PhD, a physician scientist who focuses on the genomics of therapy-related and de novo acute myeloid leukemias (AML), and molecular diagnostics; David VanderWeele, MD, PhD, who studies tumor heterogeneity, with a focus on genitourinary malignancies; Akash Patnaik, MD, PhD, who is a translational physician scientist working at the interface between laboratory-based investigations and early-phase clinical trials in prostate cancer; and Jane Churpek, MD, who is a clinician/ researcher who focuses on hereditary cancer susceptibility syndromes with an emphasis on hematological malignancies. Four new developing Shared Resources or new services were supported with CCSG Developmental Funds: the Human Imaging Research Office (HIRO), Imaging Chemistry Subcore within the Integrated Small Animal Imaging Research Resource, the development of CRISPR/Cas9 technology in the Transgenic Mouse and ES Cell Facility, and the Bioinformatics Core Facility, the latter is now proposed as a full Core. The developing Cores continue to grow and contribute to interdisciplinary research. Over the next grant period, we are requesting $300,000/year for: 1) recruitment of new investigators ($100,000); 2) Program development/Program Pilot Projects ($100,000); and 3) development of new Shared Resources and the development of new services and integration of new technologies ($100,000). These funds will be used to further the three components of our Strategic Plan: 1) developing new biomarkers, novel treatments, and new interventions to prevent cancer; 2) efficiently integrating effective treatments and interventions into medical practice; and 3) assessing the impact of these new approaches on health outcomes, and addressing cancers relevant to our catchment area. Underpinning each of these initiatives is computation- based models for cancer research and care.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Chicago
United States
Zip Code
Boisclair Lachance, Jean-François; Webber, Jemma L; Hong, Lu et al. (2018) Cooperative recruitment of Yan via a high-affinity ETS supersite organizes repression to confer specificity and robustness to cardiac cell fate specification. Genes Dev 32:389-401
Szmulewitz, Russell Z; Peer, Cody J; Ibraheem, Abiola et al. (2018) Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol 36:1389-1395
Maron, Steven B; Alpert, Lindsay; Kwak, Heewon A et al. (2018) Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. Cancer Discov 8:696-713
Kudron, Michelle M; Victorsen, Alec; Gevirtzman, Louis et al. (2018) The ModERN Resource: Genome-Wide Binding Profiles for Hundreds of Drosophila and Caenorhabditis elegans Transcription Factors. Genetics 208:937-949
Zeineddine, Hussein A; Girard, Romuald; Saadat, Laleh et al. (2018) Phenotypic characterization of murine models of cerebral cavernous malformations. Lab Invest :
Kane, Melissa; Deiss, Felicity; Chervonsky, Alexander et al. (2018) A Single Locus Controls Interferon Gamma-Independent Antiretroviral Neutralizing Antibody Responses. J Virol 92:
Xiao, Annie; Crosby, Jennie; Malin, Martha et al. (2018) Single-institution report of setup margins of voluntary deep-inspiration breath-hold (DIBH) whole breast radiotherapy implemented with real-time surface imaging. J Appl Clin Med Phys 19:205-213
Gamazon, Eric R; Trendowski, Matthew R; Wen, Yujia et al. (2018) Gene and MicroRNA Perturbations of Cellular Response to Pemetrexed Implicate Biological Networks and Enable Imputation of Response in Lung Adenocarcinoma. Sci Rep 8:733
Girard, Romuald; Zeineddine, Hussein A; Koskimäki, Janne et al. (2018) Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth. Circ Res 122:1716-1721
Day, Kasey J; Casler, Jason C; Glick, Benjamin S (2018) Budding Yeast Has a Minimal Endomembrane System. Dev Cell 44:56-72.e4

Showing the most recent 10 out of 668 publications